Clinical trials: Best Practice
Pulmonary Embolism
US Pivotal Clinical Study of the Adient Absorbable Filter for the Prevention of Pulmonary Embolism
The objective of the study is to evaluate the safety and efficacy of the Adient absorbable filter for the prevention of pulmonary embolism (PE: blood clot in the lungs).
- Trial name
- NCT05127915
- Testing
- Adient absorbable filter + best practice VTE prophylaxis, best practice VTE prophylaxis
- Where
- 2 sites in United States
- Volunteers
- 854 people, healthy volunteers welcome
- Sponsor
- Adient Medical
Malignant Abdominal Neoplasm, Malignant Head and Neck Neoplasm
Digital and Behavioral Tele-Health Tapering Program for Lowering Dependence on Opioids in Patients Undergoing Surgery
This clinical trial studies the effect of behavioral health support including tele-health in helping surgical patients taper off of prescription opioid pain medications.
- Conditions
- Malignant Abdominal Neoplasm, Malignant Head and Neck Neoplasm, Malignant Solid Neoplasm, Malignant Thoracic Neoplasm
- Trial name
- NCT04963972
- Testing
- Behavioral Intervention, Best Practice, Questionnaire Administration
- Where
- United States
- Volunteers
- 272 people
- Sponsor
- Lucid Lane, Inc
Tropical Infectious Diseases
Optimizing Sysmex Technology as an Innovative Tool to Differentiate Between Malaria (PALUdism) and BACterial Infections in a Malaria Endemic Region
Severe malaria and bacterial Blood Stream Infections (bBSI) are impossible to differentiate clinically. This poses a particular threat in low resource areas, where bBSI is often not diagnosed due to the unavailability of rapid…
- Trial name
- PALUBAC (NCT02669823)
- Testing
- None, treatment as actual best practice
- Where
- Burkina Faso
- Volunteers
- 930 people
- Sponsor
- Sysmex Europe GmbH
Leg Ulcers
Safety Evaluation of Biatain Ibu in Painful Chronic Venous Leg Ulcers
The objective of this open label extension study (extension to study DK143WS) is to evaluate the safety of Biatain Ibu during 6 -12 weeks of exposure and during a 40 - 46 weeks safety follow-up period.
- Trial name
- NCT00628004
- Testing
- Biatain Ibu, Local best practice
- Where
- 5 sites in Denmark, Germany and 1 more
- Volunteers
- 93 people
- Sponsor
- Coloplast A/S